<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82286">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01884948</url>
  </required_header>
  <id_info>
    <org_study_id>Omegaven - Zurich</org_study_id>
    <nct_id>NCT01884948</nct_id>
  </id_info>
  <brief_title>Effects of Omega-3 Fatty Acids on Outcome After Major Liver Resection</brief_title>
  <official_title>A Randomized, Double-blind Study of the Effects of Omega-3 Fatty Acids (Omegaven™) on Outcome After Major Liver Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the efficacy and safety of intravenous Omegaven™ (vs. Placebo) in reducing
      postoperative morbidity and mortality after major liver resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With two single doses of Omegaven (pre- and postoperatively) we aim to reduce postoperative
      complications measured by the CCI (Comprehensive Complication Index) and the Clavien Dindo
      classification of surgical complications. The study will include adults (more than 18 years)
      patients requiring liver resection of at least 1 segment or multiple wedge resections (≥3).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>1 month after hospital discharge</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complications will be assessed using the Comprehensive Complication Index (CCI) and the Clavien-Dindo complication classification.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">258</enrollment>
  <condition>Major Liver Surgery</condition>
  <arm_group>
    <arm_group_label>Omegaven™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omegaven™ (approval number:54750 Swissmedic)- 100ml intravenously. The first dose (Omegaven™ or placebo) is administered in the evening before surgery, the second dose at the beginning of anesthesia. The maximum infusion rate must be adjusted to bodyweight (0.5 ml Omegaven™/kg/hour).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100ml of saline is used as a placebo comparator and administered as described above.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omegaven™</intervention_name>
    <arm_group_label>Omegaven™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Requiring liver resection of at least 1 segment or multiple wedge resections (=3)

          -  &gt; 18 years of age

          -  No coagulopathy (INR &lt; 1.2, platelets &gt;150'000 x10E3/µl)

          -  Understands local language

        Exclusion criteria:

          -  Liver resections &lt;1 segment

          -  Wedge resections (&lt;3)

          -  Liver cirrhosis

          -  Coagulopathy (INR &gt; 1.2, platelets &lt; 150'000 x10E3/µl)

          -  Hypertriglyceridemia (&gt; 5.0 mmol/l)

          -  Hypersensitivity or allergy to Omegaven™ or any fish oil or lipid emulsions

          -  Known allergy to egg protein

          -  Pregnancy

          -  Nursing women

          -  Renal failure(estimated GFR &lt; 30 ml/min/1.73m2)

          -  Medication impairing platelets aggregation

          -  Cannot understand local language
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Alain Clavien, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Visceral and Transplantation Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Linecker, MD</last_name>
    <phone>0041 442553300</phone>
    <email>Michael.Linecker@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierre Alain Clavien, MD PhD</last_name>
    <phone>0041 442553300</phone>
    <email>clavien@access.uzh.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Visceral and Transplantation Surgery</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.kompendium.ch/mpro/mnr/8980/html/de</url>
    <description>Omegaven</description>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>June 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>at least 1 segment</keyword>
  <keyword>multiple wedge resections (≥3)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
